Suchergebnisse - "Fu, Qihan"

PubPharm (54)

1

Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis : A multi-institutional retrospective study

enthalten in: Cancer letters | 2024

von Wang, Y. | Sun, X. | Chen, C. | +19

2

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma : a phase I trial

enthalten in: EClinicalMedicine | 2023

von Fu, Q. | Zheng, Y. | Fang, W. | +17

3

Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer : The Randomized Phase II CISPD3 Trial

enthalten in: Annals of surgical oncology | 2023

von Fu, Q. | Chen, Y. | Huang, D. | +13

4

ASO Visual Abstract: Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial

enthalten in: Annals of surgical oncology | 2023

von Fu, Q. | Chen, Y. | Huang, D. | +13

5

ASO Visual Abstract: Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial

enthalten in: Annals of surgical oncology | 2023

von Fu, Q. | Chen, Y. | Huang, D. | +13

6

An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis

enthalten in: Cell reports. Medicine | 2023

von Bao, X. | Wang, D. | Dai, X. | +19

7

Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial

enthalten in: Annals of surgical oncology | 2023

von Fu, Q. | Chen, Y. | Huang, D. | +13

8

Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial

enthalten in: Annals of surgical oncology | 2023

von Fu, Q. | Chen, Y. | Huang, D. | +13

9

Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial

enthalten in: Annals of surgical oncology | 2023

von Fu, Q. | Chen, Y. | Huang, D. | +13

10

Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients : a randomized-controlled open-label Phase II study

enthalten in: Gastroenterology report | 2023

von Zhang, H. | Tong, Z. | Liu, L. | +7

1
2
3
4
5
6
Nächster »
[6]